Hagens Berman has opened a legal investigation into CVRx following a U.S. Department of Justice Civil Investigative Demand concerning possible false claims and kickbacks related to its heart failure device, Barostim. The company also cut its 2026 revenue guidance sharply, revealed sales force problems, and saw a major Medicare Advantage approval drop. After these disclosures, CVRx's stock fell 59%, and the Chief Revenue Officer was abruptly fired. The investigation will examine if CVRx misled investors about its sales and reimbursement status and the link between the DOJ probe and the CRO's termination.
BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...
Raymond James increased its price target for SBA Communications to $271 from $264, signaling a 68.6% upside from the current share price of $160.74. The growth is driven by rising mobile data demand, network expansions by wireless carriers, and stead...
SPX Technologies (NYSE: SPXC) recently traded near its 52-week low around $170, down about 1.6% from the previous close. Despite this, several analysts maintain positive outlooks with price targets ranging from $250 to $301, indicating potential upsi...
PBF Energy's shares have surged 173% over the past year, nearing record highs due to stronger refining margins and improved quarterly results. The company reduced its net term debt by over $1.4 billion in Q2 2026, refinanced notes, and maintained nea...
J D Wetherspoon reported an 8.6% increase in like-for-like sales in the first nine weeks of its new financial year, helped by favorable weather. However, profit before tax fell 28% to £58.60 million despite a 5.2% revenue rise to £2.24 billion, mainl...
